BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28027893)

  • 21. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.
    Titeux M; Pendaries V; Zanta-Boussif MA; Décha A; Pironon N; Tonasso L; Mejia JE; Brice A; Danos O; Hovnanian A
    Mol Ther; 2010 Aug; 18(8):1509-18. PubMed ID: 20485266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
    Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
    Osborn MJ; Newby GA; McElroy AN; Knipping F; Nielsen SC; Riddle MJ; Xia L; Chen W; Eide CR; Webber BR; Wandall HH; Dabelsteen S; Blazar BR; Liu DR; Tolar J
    J Invest Dermatol; 2020 Feb; 140(2):338-347.e5. PubMed ID: 31437443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
    Woodley DT; Krueger GG; Jorgensen CM; Fairley JA; Atha T; Huang Y; Chan L; Keene DR; Chen M
    J Invest Dermatol; 2003 Nov; 121(5):1021-8. PubMed ID: 14708601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
    Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
    Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors.
    Baldeschi C; Gache Y; Rattenholl A; Bouillé P; Danos O; Ortonne JP; Bruckner-Tuderman L; Meneguzzi G
    Hum Mol Genet; 2003 Aug; 12(15):1897-905. PubMed ID: 12874109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras.
    Petrova A; Georgiadis C; Fleck RA; Allison L; McGrath JA; Dazzi F; Di WL; Qasim W
    J Invest Dermatol; 2020 Jan; 140(1):121-131.e6. PubMed ID: 31326396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model.
    Liao Y; Ivanova L; Sivalenka R; Plumer T; Zhu H; Zhang X; Christiano AM; McGrath JA; Gurney JP; Cairo MS
    Stem Cells Transl Med; 2018 Jul; 7(7):530-542. PubMed ID: 29745997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa.
    Atanasova VS; Jiang Q; Prisco M; Gruber C; Piñón Hofbauer J; Chen M; Has C; Bruckner-Tuderman L; McGrath JA; Uitto J; South AP
    J Invest Dermatol; 2017 Sep; 137(9):1842-1849. PubMed ID: 28549954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
    Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
    Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Liemberger B; Bischof J; Ablinger M; Hainzl S; Murauer EM; Lackner N; Ebner P; Kocher T; Nyström A; Wally V; Mayr E; Guttmann-Gruber C; Hofbauer JP; Bauer JW; Koller U
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.
    Cogan J; Weinstein J; Wang X; Hou Y; Martin S; South AP; Woodley DT; Chen M
    Mol Ther; 2014 Oct; 22(10):1741-52. PubMed ID: 25155989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
    Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
    J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
    J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
    Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
    J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.
    Perdoni C; Osborn MJ; Tolar J
    Transl Res; 2016 Feb; 168():50-58. PubMed ID: 26073463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Murine type VII collagen distorts outcome in human skin graft mouse model for dystrophic epidermolysis bullosa.
    Bremer J; Kramer D; Eichhorn DS; Gostyński A; Diercks GFH; Jonkman MF; van den Akker PC; Pasmooij AMG
    Exp Dermatol; 2019 Oct; 28(10):1153-1155. PubMed ID: 30019435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.
    Tolar J; Xia L; Riddle MJ; Lees CJ; Eide CR; McElmurry RT; Titeux M; Osborn MJ; Lund TC; Hovnanian A; Wagner JE; Blazar BR
    J Invest Dermatol; 2011 Apr; 131(4):848-56. PubMed ID: 21124339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stable nonviral genetic correction of inherited human skin disease.
    Ortiz-Urda S; Thyagarajan B; Keene DR; Lin Q; Fang M; Calos MP; Khavari PA
    Nat Med; 2002 Oct; 8(10):1166-70. PubMed ID: 12244305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.
    Dakiw Piaceski A; Larouche D; Ghani K; Bisson F; Cortez Ghio S; Larochelle S; Moulin VJ; Caruso M; Germain L
    Eur Cell Mater; 2018 Feb; 35():73-86. PubMed ID: 29441510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.